Core Viewpoint - Weigao Blood Products (603014.SH) plans to acquire 100% equity of Weigao Puri through a share issuance for a total consideration of 8.511 billion yuan, with the share price set at 31.29 yuan per share, resulting in approximately 272 million shares being issued, which will account for 39.43% of the total share capital post-issuance [1] Group 1 - The transaction will change the controlling shareholder from Weigao Group to Weigao Shares, while the actual controller remains Chen Xueli, indicating no change in control [1] - The acquisition will expand the company's main business to include pre-filled drug delivery systems and automatic safety drug delivery systems, enhancing its pharmaceutical packaging capabilities [1] Group 2 - Financial projections for the target company indicate revenues of 1.43 billion yuan, 1.67 billion yuan, and 1.41 billion yuan for the years 2023, 2024, and the first nine months of 2025, respectively, with net profits of 483 million yuan, 581 million yuan, and 486 million yuan for the same periods [1] - The assessed value of the target assets shows a 192.90% appreciation based on the income approach as of September 30, 2025 [1] - The transaction counterpart has committed to net profits for Weigao Puri of 640 million yuan, 720 million yuan, and 784 million yuan for the years 2026 to 2028, with adjustments if the transaction is delayed to 2027 [1]
溢价192.9%！威高血净拟85.11亿元收购关联方威高普瑞 2026-2028年业绩承诺超21亿